435,000 potential procedures not including Vitiligo. That’s a remarkable jump from 25,000 burns procedures (when Avita reached $56 per share US). Then, another 500,000 potential procedures expected with Vitiligo. I’m still concerned about potential recession and Go delay, but with the addition of PermeaDerm and international sales, there seems to be a path to high rewards in the near term. Also, Avita wants to broaden its sales portfolio, so PermeaDerm may be the first of several complimentary skin healing products that Avita can sell, which will maximize profits from existing and future sales reps. Does anyone have the analysts’ reports from those that upgraded?
Ann: AVITA Medical Q4 2023 Investor Presentation, page-3
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.66 |
Change
0.160(6.40%) |
Mkt cap ! $165.4M | |||
| Open | High | Low | Value | Volume |
| $2.58 | $2.66 | $2.57 | $745.0K | 285.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $2.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.66 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 23/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.62 |
Change
0.160 ( 3.91 %) |
||||
| Open | High | Low | Volume | ||
| $2.58 | $2.63 | $2.57 | 25062 | ||
| Last updated 15.59pm 23/05/2024 ? | |||||
| AVH (ASX) Chart |